A

Artios

97 employees

Artios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies.

Basic info

Industry

biotechnology research

Sectors

Medical Device
Biotechnology
DNA damage response
Biopharma

Date founded

2016

Funding rounds raised

Total raised

$152M

from 19 investors over 19 rounds

A

Artios raised $152M on July 27, 2021

Investors: Schroders Capital, Omega Funds, Tetragon Financial Group Limited, Piper Sandler, Soleus Capital Management, L.P., Sofinnova Partners, RTW Investments, LP and SV Life Sciences

A

Artios raised $30M on December 3, 2020

Investors: Merck Group

A

Artios raised $83M on August 10, 2018

Investors: Arix Bioscience plc, IP Group plc, EQT Life Sciences, Andera Partners and SV Life Sciences

A

Artios raised $33M on September 21, 2016

Investors: Imperial College London, SV Life Sciences, M Ventures and Arix Bioscience plc

A

Artios raised undisclosed on September 6, 2016

Investors: SV Life Sciences

FAQ